AASLD Hot Updates on MASLD from the 2023 Annual Meeting
Editor's Note: On November 7, 2023, at 12:30 PM local time in Boston, the American Association for the Study of Liver Diseases (AASLD) held its sole pre-conference press briefing on…
AASLD Exclusive Interview | Dr.Mark Yarchoan: Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy
Editor's Note: At the recently concluded international annual flagship event in the field of hepatology – the American Association for the Study of Liver Diseases Annual Meeting (AASLD 2023), Professor…
Dr. Junqi Niu’s Team: Revealing Changes in Human Hepatic Stellate Cells, Discovering Potential Diagnostic and Therapeutic Targets for Liver Fibrosis
Liver cirrhosis is a prevalent condition worldwide, closely associated with the progression of chronic liver diseases and a critical precursor to liver cell carcinoma. Due to its insidious onset and…
AASLD 2023 | Professor Zhihua Liu’s Team: Revealing the Dynamic Changes in T-Cell Immunity during Pregnancy and Postpartum Period in Women with Chronic HBV Infection and Its Relationship with Infection Status
Editor's Note: The 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting has recently concluded in Boston, USA. A study in the field of immunology related to hepatitis…
Dr. Wai-Kay Seto’s team: Multiple Studies on Hepatic Diseases Management with New Hepatitis B Drugs, Fatty Liver Monitoring, and Liver Cancer Risk Factors
The 58th Annual Meeting of the European Association for the Study of the Liver (EASL2023) and the EASL Congress 2023 have come to a close. During this conference, Dr. Wai-Kay…
Dr. Wenshi Wang’s Team: Three Latest Research Findings on Hepatitis D and Hepatitis E Included in Conference Exchange
Hepatitis D (HDV) is a viral hepatitis caused by hepatitis D virus (HDV) infection, often occurring as a co-infection or superinfection with hepatitis B virus (HBV). Approximately 90% of chronic…
Dr. Minghua Zheng’s Team: AI-Based Digital Pathology Provides New Insights into NASH Fibrosis Reversal Induced by Lifestyle Intervention
Non-Alcoholic Steatohepatitis (NASH) is a common cause of chronic liver disease, and the degree of liver fibrosis is an important factor determining its clinical prognosis. Lifestyle intervention is the cornerstone…
Dr. Yong-an Ye ‘s Team: Using Machine Learning-Based Predictive Models to Identify Early Virological Recurrence Risk in Chinese Chronic Hepatitis B Patients After Entecavir Discontinuation
Currently, most chronic hepatitis B (CHB) patients cannot achieve a cure. While guidelines suggest that some CHB patients can discontinue nucleos(t)ide analogs (NAs) after consolidation therapy, virological recurrence remains common.…
Discovery and Verification of HBV Auxiliary Receptor NRP1
Hepatitis B Virus (HBV) infection is one of the main causes of liver diseases, affecting approximately 292 million people worldwide who are chronic carriers of HBV, leading to severe conditions like liver cirrhosis and primary liver cancer. The infection process of HBV relies on the binding of the viral envelope proteins to receptors on the cell surface. Therefore, interfering with the binding of the viral envelope proteins and receptors can be an effective antiviral strategy. During the 15th Chronic Viral Hepatitis Antiviral Treatment Challenges and Hot Topics Academic Conference, held in Chongqing from November 17-19, 2023, and organized by the Chinese Medical Journal Company Ltd., Editorial Office of the Chinese Journal of Hepatology, and co-organized by the Hepatitis Group of the Chinese Society of Hepatology, the Second Affiliated Hospital of Chongqing Medical University, and the Chongqing Medical University Institute of Viral Hepatitis, Dr. Ailong Huang, President of Chongqing Medical University, shared his team's latest research findings on how HBV depends on various receptors and auxiliary receptors to infect cells. This research provides new insights into the mechanism of HBV invasion and the development of novel drugs to block HBV infection.
Interpretation of “Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma”
On December 9-10, 2023, the "Huaxia Shanghai Liver Disease Forum and Shanghai Liver Disease Summit" was successfully held, sponsored by the Huaxia Liver Disease Association, organized by the Shanghai "Liver" Magazine, and co-organized by the Shanghai Medical Association Hepatology Subspecialty Branch, Shanghai Physicians Association Infectious Disease Physicians Branch, Shanghai Infectious Disease Clinical Quality Control Center, and the Long Triangle Representative Office of the China Association of Non-Public Medical Institutions. At the conference, Dr.Xiufeng Liu from the Medical Area of the Qinhuai Hospital of the Eastern Theater General Hospital of the People's Liberation Army provided a detailed interpretation of the "Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma," which was newly issued in China. This journal has invited Dr.Xiufeng Liu to conduct an in-depth interview to introduce the consensus's recommendations regarding first-line and subsequent-line treatment options for liver cancer immunotherapy, as well as the assessment of treatment efficacy and other hot topics. The following content summarizes these insights for readers.